To promote intracellular delivery of neoantigen peptides and CDN STING agonists to enhance CD8+ T-cell responses, Shae et al. designed a synthetic tumor nanovaccine platform (nanoSTING-vax) [109]. Here, CD8A is linked to neoplasm.